Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) EBITDA: 2015-2025

Historic EBITDA for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -$19.9 million.

  • AC Immune's EBITDA fell 331.39% to -$19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.5 million, marking a year-over-year decrease of 107.51%. This contributed to the annual value of -$59.8 million for FY2024, which is 1.10% up from last year.
  • AC Immune's EBITDA amounted to -$19.9 million in Q3 2025, which was up 14.01% from -$23.1 million recorded in Q2 2025.
  • AC Immune's 5-year EBITDA high stood at $8.6 million for Q3 2024, and its period low was -$24.6 million during Q4 2021.
  • Moreover, its 3-year median value for EBITDA was -$19.9 million (2025), whereas its average is -$16.5 million.
  • The largest annual percentage gain for AC Immune's EBITDA in the last 5 years was 149.47% (2024), contrasted with its biggest fall of 432.39% (2024).
  • AC Immune's EBITDA (Quarterly) stood at -$24.6 million in 2021, then grew by 20.97% to -$19.4 million in 2022, then spiked by 79.43% to -$4.0 million in 2023, then plummeted by 432.39% to -$21.3 million in 2024, then plummeted by 331.39% to -$19.9 million in 2025.
  • Its EBITDA was -$19.9 million in Q3 2025, compared to -$23.1 million in Q2 2025 and -$21.3 million in Q1 2025.